Alexza Pharmaceuticals Inc. Alexza Pharmaceuticals is a rapidly emerging pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS conditions. All of our product candidates are based on our proprietary technology, the Staccato® system. The Staccato system vaporizes excipient-free drugs to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the ideal particle size of the aerosol, the pure drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous (IV) administration but with greater ease, patient comfort and convenience. Alexza's lead program is ADASUVE™ (Staccato loxapine or AZ-004), being developed for the acute treatment of agitation in patients with schizophrenia or bipolar disease. During 2011, Alexza resubmitted the ADASUVE NDA and the ADASUVE MAA in Europe. Alexza has a U.S. PDUFA goal date for ADASUVE of February 4, 2012. Staccato nicotine (Preclinical) |
http://www.alexza.com/ http://finance.yahoo.com/q/ks?s=ALXA Alexza Pharmaceuticals, Inc., a development stage company, focuses on the development and commercialization of products for the treatment of acute and intermittent conditions primarily in the United States. Its technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The company has four product candidates in clinical development: AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches; AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder; AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia; and AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain. Its product candidate AZ-001 completed Phase IIb Clinical Trial; AZ-004 completed Phase IIa Clinical Trial; AZ-002 is in Phase IIa Clinical Trials; and AZ-003 completed a Phase I Clinical Trial. Alexza Pharmaceuticals has a development agreement with Autoliv ASP, Inc. for the development of heat packages that can be incorporated into proprietary single dose drug delivery device. The company, formerly known as FaxMed, Inc., was founded in 2000. FaxMed changed its name to Alexza Corporation in June 2001 and to Alexza Molecular Delivery Corporation in December 2001. Further, it changed its name to Alexza Pharmaceuticals, Inc. in July 2005. The company is based in Palo Alto, California.
 | Thomas B. King
President, Chief Executive Officer
Thomas B. King has served as our President, Chief Executive Officer and a member of our Board since June 2003. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development company. From January 1994 to February 2001, Mr. King held various senior executive positions, including President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors at Anesta Corporation, a publicly traded pharmaceutical company, until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King received an M.B.A. from the University of Kansas and a B.A. in chemistry from McPherson College. |
[